Postoperative Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Postoperative Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-15FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
The FDA approved a supplemental application for ondansetron hydrochloride, a generic antiemetic, with Onesource Specialty Pharma Limited as …
-
FDA approval · 2026-04-15FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
The FDA approved a supplemental application for ondansetron hydrochloride from Onesource Specialty Pharma Limited under ANDA078257.
-
FDA approval · 2026-04-08FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
FDA approved a supplemental application for ondansetron (generic) from West-Ward Pharmaceuticals Corp.
-
FDA approval · 2026-04-08FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
The FDA approved a supplemental application for ondansetron filed by West-Ward Pharmaceuticals Corp. This action updates the product’s regul…
-
FDA approval · 2026-04-03FDA Approved: ONDANSETRON — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for Ondansetron submitted by PAI Holdings, LLC dba PAI Pharma (ANDA078127). This action confirms reg…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-03-02FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ondansetron hydrochloride from Aurobindo Pharma Limited, confirming labeling for this generic an…
-
FDA approval · 2026-02-25FDA Approved: ONDANSETRON — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approves a supplemental application for a generic ondansetron hydrochloride product from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2026-02-09FDA Approved: SCOPOLAMINE TRANSDERMAL SYSTEM — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved a supplemental application for Scopolamine Transdermal System from Padagis Israel Pharmaceuticals Ltd.
-
FDA approval · 2025-11-24FDA Approved: ONDANSETRON — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for ondansetron from Rising Pharma Holdings, Inc., under the existing ANDA.
-
FDA approval · 2025-11-18FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for ondansetron filed by Hospira, approving modifications to an already approved product under an AN…
-
FDA approval · 2025-11-18FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA granted Hospira, Inc. a supplemental approval for ondansetron (ONDANSETRON) under an ANDA.
-
FDA approval · 2025-11-17FDA Approved: ONDANSETRON — Supplemental Application (JVET PHARMACEUTICALS LLC)
FDA approved a supplemental application for ondansetron from JVET Pharmaceuticals LLC under an ANDA (generic). The approval covers the use o…
-
EMA approval · 2025-10-24EMA Authorised: Emend (aprepitant) — Merck Sharp & Dohme B.V.
The EMA authorised Emend (aprepitant) by Merck Sharp & Dohme B.V. for prevention of vomiting and nausea in cancer patients, including postop…
-
FDA approval · 2025-10-23FDA Approved: ONDANSETRON — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for ondansetron hydrochloride (ONDANSETRON) by NorthStar Rx LLC under ANDA078776. This confirms appr…
-
FDA approval · 2025-09-17FDA Approved: ONDANSETRON — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for ondansetron under ANDA078127 held by PAI Holdings (PAI Pharma), authorizing an amendment to the …
-
FDA approval · 2025-09-16FDA Approved: ONDANSETRON — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved a supplemental application for ondansetron from Qilu Pharmaceutical Co., Ltd. under ANDA203711.
-
FDA approval · 2025-09-15FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for ondansetron hydrochloride from Hikma Pharmaceuticals USA Inc.
-
FDA approval · 2025-09-09FDA Approved: ONDANSETRON — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark's supplemental application for ondansetron, resulting in an approval update to its existing product labeling/indic…
-
FDA approval · 2025-09-09FDA Approved: ONDANSETRON — Supplemental Application (AvKARE)
The FDA approved a supplemental application for ondansetron by AvKARE, enabling continued use of this generic antiemetic product.
-
FDA approval · 2025-09-08FDA Approved: PROCHLORPERAZINE MALEATE — Original Application (Aurobindo Pharma Limited)
The FDA approved Aurobindo Pharma Limited's original ANDA for prochlorperazine maleate, allowing the generic antiemetic/antipsychotic to be …
-
FDA approval · 2025-08-20FDA Approved: SCOPOLAMINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for scopolamine filed by Zydus Pharmaceuticals USA Inc., indicating an update to an existing AND…
-
FDA approval · 2025-07-03FDA Approved: APREPITANT — Supplemental Application (BluePoint Laboratories)
The FDA approved BluePoint Laboratories' supplemental application for aprepitant (ANDA 207777), allowing a generic version of this antiemeti…
-
FDA approval · 2025-06-10FDA Approved: TRANSDERM SCOP — Supplemental Application (Baxter Healthcare Corporation)
The FDA approved a supplemental application for TRANSDERM SCOP (scopolamine) from Baxter Healthcare Corporation.
-
FDA approval · 2025-06-09FDA Approved: SCOPOLAMINE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved a generic scopolamine product from Amneal Pharmaceuticals NY LLC under an original ANDA (ANDA218384).
-
FDA approval · 2025-05-23FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for Palonosetron hydrochloride submitted by Mylan Institutional LLC. This action updates the pro…